Head and Neck Diseases

Manel Maños Pujol

PRINCIPAL INVESTIGATORS
  • Lorena Arribas Hortigüela
  • Marc Oliva Bernal
  • Miren Taberna Sanz
  • Ricard Mesia Nin
CLINICAL RESEARCHERS
  • Carlos Arranz Obispo
  • Jesus Brenes Castro
  • Alicia Lozano Borbalas
  • Antoni Mari Roig
  • Maria Plana Serrahima
  • Laura Rodriguez Bel
  • Miriam Handam Zavarce
  • Henry Lares Archer
  • Enric Cisa Lluis
  • Oriol Bermejo Sergu
  • Monica Cos Domingo
  • Francesc Cruellas Taischik
  • Montserrat Goma Gallego
  • Xavier Gonzalez Compta
  • Javier Skufca Vieitez
  • Mireia Melero Luque
  • Anna Farre Guiu
  • Julio Nogues Orpi
  • Jordi Tornero Salto
EXTERNAL COLLABORATORS
  • Aleix Rovira Casas
PREDOCTORAL RESEARCHERS
  • Gabriel Huguet Llull
  • Francisco J Cuesta Gonzalez
SCIENTIFIC SUPPORT
  • Maria Sospedra Martinez
Cancer
Oncobell

Scientific production

35

PAPERS

Impact factor: 249,065

6 PUBLICATIONS IN FIRST DECILE

16 PUBLICATIONS IN FIRST QUARTILE

24 PUBLICATIONS IN OPEN ACCESS

Selected publications

  • Piulats JM, Espinosa E, Merino LD, Varela M, Carrion LA, Martin Algarra S, Castro RL, Curiel T, Rodriguez Abreu D, Redrado M, Goma M, Rullan AJ, Gonzalez AC, Berrocal Jaime A. Nivolumab Plus Ipilimumab for Treatment-Naive Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402). J Clin Oncol. 2021;39(6):586-598. doi:10.1200/JCO.20.00550. IF:44,54.
  • Guigay J, Auperin A, Fayette J, Saada Bouzid E, Lafond C, Taberna M, Geoffrois L, Martin L, Capitain O, Cupissol D, Castanie H, Vansteene D, Schafhausen P, Johnson A, Even C, Sire C, Duplomb S, Evrard C, Delord JP, Laguerre B, Zanetta S, Chevassus Clement C, Fraslin A, Louat F, Sinigaglia L, Keilholz U, Bourhis J, Mesia R, G, A, TTCC, UniCancer Head Neck GRP. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2021;22(4):463-475. doi:10.1016/S1470-2045(20)30755-5. IF:41,32.
  • Oliva M, Chepeha D, Araujo DV, Diaz Mejia JJ, Olson P, Prawira A, Spreafico A, Bratman SV, Shek T, de Almeida J, Hansen AR, Hope A, Goldstein D, Weinreb I, Smith S, Perez Ordonez B, Irish J, Torti D, Bruce JP, Wang B, Fortuna A, Pugh TJ, Der Torossian H, Shazer R, Attanasio N, Au QY, Tin A, Feeney J, Sethi H, Aleshin A, Chen I, Siu LL. Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study. J Immunother Cancer. 2021;9(10):doi:10.1136/jitc-2021-003476. IF:13,75.
  • Oliva M, Schneeberger PHH, Rey V, Cho M, Taylor R, Hansen AR, Taylor K, Hosni A, Bayley A, Hope AJ, Bratman SV, Ringash J, Singh S, Weinreb I, Perez Ordoñez B, Chepeha D, Waldron J, Xu W, Guttman D, Siu LL, Coburn B, Spreafico A. Transitions in oral and gut microbiome of HPV+ oropharyngeal squamous cell carcinoma following definitive chemoradiotherapy (ROMA LA-OPSCC study). Br. J. Cancer. 2021;124(9):1543-1551. doi:10.1038/s41416-020-01253-1. IF:7,64.
  • Arribas L, Plana M, Taberna M, Sospedra M, Vilarino N, Oliva M, Pallares N, Tampan A, Del Rio LM, Mesia R, Baracos V. Predictive Value of Skeletal Muscle Mass in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients Treated With Immune Checkpoint Inhibitors. Front Oncol. 2021;11699668-699668. doi:10.3389/fonc.2021.699668. IF:6,24.

Research highlights

PROJECTS

6 Competitive projects
3 Non competitive projects
56 clinical trials

PUBLISHED WORKS

1 Thesis

2 Clinical guidelines

Selected projects

  • 21FIS004. CONTRATOS PREDOCTORALES DE FORMACION EN INVESTIGACION EN SALUD (PFIS). (FI20/00103). ISCIII. 2021-2024. IP:MESIA NIN,RICARD.
  • 21FIS023. CONTRATOS RIO HORTEGA. (CM20/00120). ISCIII. 2021-2022. IP:MESIA NIN,RICARD.
  • 21DPS001. PRESERVE: AI for new signatures and models for tailored organ preservation approaches in laryngeal and hypopharyngeal cancer. (SLD043/20/000001). ASST SPEDALI CIVILI DI BRESCIA (ASST-SC ); ATHENS TECHNOLOGY CENTER (ATC); DIR.GEN.SALUT PUBLICA, DEP.SALUT GE; FUNDACIO IDIBELL; ISTITUTO EUROPEO DI ONCOLOGIA; UNIVERSITY OF LEIPZIG; UNIVERSITY OF OSLO (UIO). 2021-2023. IP:MESIA NIN,RICARD.
  • 20PSJ025. Papel de la microbiota oral como biomarcador en el cáncer de orofaringe VPH-relacionado y no relacionado. SOCIEDAD ESPAÑOLA DE ONCOLOGIA MEDICA. 2020-2022. IP:TABERNA SANZ,MIREN.
  • 20FIS005. Valor predictivo y pronóstico de la composición corporal y el hábito tabáquico en pacientes de cáncer de orofaringe según su asociación al virus del papiloma humano. (PI19/00363). ISCIII. 2020-2022. IP:MESIA NIN,RICARD.